PI Industries Limited

The global crop protection market faced challenges from climate change, commodity price volatility, and pricing pressure, while the domestic market saw volume growth but continued price pressure. PI Industries is strategically pivoting from an agricultural sciences company to a life sciences company, targeting an expanded addressable market of $15-20 billion in innovative agrochemical products and multi-billion-dollar markets in pharmaceuticals, CRDMO, electronic chemicals, and biologicals. This transformation aims to enhance its global position in technology, research, and manufacturing.

For Q4 FY25, PI Industries reported a revenue of ₹1,787.1 crores, marking a 3% YoY growth, with a 3-year CAGR of 9%. Consolidated EBITDA grew 3% with a healthy margin of 25.6%. For the full year FY25, revenue reached ₹7,977.8 crores, a 4% YoY increase, and consolidated EBITDA grew 8% to 27.4%. However, consolidated PAT for FY25 marginally declined by 1% to ₹1,660.2 crores, primarily due to a higher effective tax rate of 22.5% compared to 11.2% in the previous year.

New product commercialization remained a key growth driver, with Agchem exports seeing 23% YoY growth in Q4 FY25 and 31% YoY for the full year. The company has commercialized over 15 molecules in the last three years, with approximately 50% of new enquiries being non-agricultural chemical molecules. The biologicals business grew 20% YoY in FY25 and is targeted to increase 5x in the next five years, from approximately ₹250 crores to ₹1,000-1,200 crores.

PI Industries is building a fully integrated Pharma CRDMO platform, aiming for accelerated growth through high-quality assets and an excellent leadership team. The company's first NCE from India is currently in Phase 3 trials, with commercialization expected in the first country within the next couple of years. The pharma business, while showing strong sequential revenue growth of 33% to ₹85 crores in Q4 FY25, is not expected to turn EBITDA positive in FY26, with positive trends anticipated in FY27-FY28.

The company maintains a healthy balance sheet with a net cash balance of ₹4,092.6 crores. Planned CAPEX for FY26 is in the range of ₹800-900 crores, with approximately ₹100 crores allocated to PIHS and pharma business, and the balance to Ag-Chem manufacturing. The acquisition of Plant Health Care, specializing in peptides, was a strategic step towards building a platform technology-based biologicals product solutions company.

For FY26, PI Industries anticipates mid-single-digit revenue growth, acknowledging industry headwinds^🌐 and climatic uncertainties. The consolidated EBITDA margin is expected to be around 25%. The company aims for 15-20% growth in its domestic business, which is twice the industry average. Working capital days are targeted to improve from 73 days to 65-70 days, and the effective tax rate is projected to be 22-23% for the next 2-3 years.